## EFX: Equifax, Inc. - XLI: Industrials

### Executive Summary

VALUE thesis: PEG 1.05 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($210.04)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Equifax (NYSE: EFX) rolls out Income Qualify to give lenders earlier income and job data**
- Source: Stock Titan | 20251210T124736 | Bullish | Relevance: 99%
-  Equifax (NYSE: EFX) has launched Income Qualify, a new product that provides verified income and employment data from The Work Number to mortgage lenders during the prequalification and pre-approval phases. This initiative aims to speed up initial assessments, reduce borrower burden, and help lenders manage costs. Additionally, Equifax announced it will offer VantageScore 4.0 mortgage credit scores at a significant discount compared to FICO 2026 prices, committing to a $4.50 price for two years, and including a free VantageScore with each FICO score purchased.

**2. Arrowstreet Capital Limited Partnership Raises Stock Holdings in Equifax, Inc. $EFX**
- Source: MarketBeat | 20251210T084423 | Somewhat-Bullish | Relevance: 99%
- Arrowstreet Capital Limited Partnership significantly increased its stake in Equifax, Inc. (NYSE:EFX) by 106.6% in the second quarter, bringing its total holdings to 34,070 shares valued at $8,837,000. This move is part of broader institutional investor activity in the credit services provider, which currently holds a "Moderate Buy" rating from analysts with an average price target of $276.40. Despite insider stock sales totaling over $12.5 million recently, Equifax reported strong third-quarter earnings, beating consensus estimates with $2.04 EPS on $1.54 billion in revenue.

**3. Equifax Introduces Income Qualify to Deliver Insights Earlier in the Mortgage Lending Process and Help Lenders Manage Costs**
- Source: PR Newswire | 20251210T130758 | Bullish | Relevance: 99%
-  Equifax has launched Income Qualify, a new product designed for mortgage lenders to gain income and employment insights earlier in the prequalification and pre-approval phases. This offering leverages data from The Work Number, helping lenders assess borrower eligibility faster, reduce risk, manage costs, and support home ownership affordability. The product provides key data points such as employer name, tenure, and prior-year total income to streamline the lending process.

**4. CIBC Asset Management Inc Lowers Holdings in Equifax, Inc. $EFX**
- Source: MarketBeat | 20251211T101115 | Somewhat-Bullish | Relevance: 98%
-  CIBC Asset Management Inc reduced its stake in Equifax, Inc. (NYSE:EFX) by 4.7% in the second quarter, now holding 202,326 shares valued at $51.8 million. This comes as company insiders, including CEO Mark W. Begor, have also sold significant amounts of Equifax stock. The company recently reported strong quarterly earnings, beating analyst expectations, and declared a quarterly dividend of $0.50 per share.

**5. Amundi Buys 23,161 Shares of Equifax, Inc. $EFX**
- Source: MarketBeat | 20251209T080808 | Neutral | Relevance: 98%
- Amundi has increased its stake in Equifax, Inc. (NYSE:EFX) by 11.2%, acquiring an additional 23,161 shares, bringing its total holdings to 230,283 shares valued at approximately $60.4 million. Several other institutional investors also adjusted their positions in the credit services provider during the second quarter. Meanwhile, company insiders, including CEO Mark W. Begor and EVP Jamil Farshchi, sold a significant number of shares, while Wall Street analysts provided a "Moderate Buy" consensus rating with a target price of $276.40.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | BMO Capital | $234 | $245 | -4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | BMO Capital | main | Market Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($0.90M) |
| Sells | 5 ($1.53M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+2.1%)
- Capital Internationa: 8.5% (-0.4%)
- Blackrock Inc.: 7.5% (+1.4%)
- Price (T.Rowe) Assoc: 4.9% (+1.0%)
- Harris Associates L.: 4.8% (+14.2%)

### Key Risks

1. Long-term trend broken: trading 9.2% below SMA200.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +4.0% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.05 suggests fair value with growth premium. Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $27.2B |
| Beta | 1.59 |
| 52W Range | $199.98 - $281.07 |
| Short Interest | 3.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.05 |
| Forward P/E | 25.0 |
| Current P/E | 29.0 |
| YoY Growth | 16.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -1.2% to 2.7% (+4.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.3pp (needs >4.0% for momentum thesis). MRS_5 at 3.4% confirms short-term momentum alignment. AM_20 at 5.0% shows strong absolute momentum above own 20MA. Below SMA200 (0.91x), long-term trend not supportive. MACD histogram positive (1.68), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.72% (CS: 63) | Neutral |
| RSI_14 | 60.4 | Neutral |
| MACD Histogram | 1.68 | Bullish |
| vs SMA20 | 1.049x | Above |
| vs SMA50 | 1.012x | Above |
| vs SMA200 | 0.908x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $220.60
- **Stop Loss:** $210.04 (4.8% risk)
- **Target:** $241.72 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 130
- **Position Value:** $28,678.00
- **Portfolio %:** 28.68%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-05 (Est: $2.04)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.94 | $2.04 | +5.3% |
| 2025Q2 | $1.92 | $2.00 | +4.1% |
| 2025Q1 | $1.40 | $1.53 | +9.0% |
| 2024Q4 | $2.10 | $2.12 | +1.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*